| Flavonoids — a large class of plant polyphenols (natural products) including flavonols (quercetin, kaempferol), flavones (apigenin, luteolin), flavanones (naringenin), isoflavones (genistein), flavan-3-ols (EGCG/catechins), and anthocyanins. Sources: fruits/berries, tea/cocoa, legumes, herbs, and standardized extracts.
Primary mechanisms (conceptual rank):
1) Redox signaling modulation (often hormetic: low-dose NRF2 ↑; high-dose ROS ↑ in cancer)
2) Anti-inflammatory transcription suppression (NF-κB ↓; cytokines ↓)
3) Kinase signaling modulation (PI3K/AKT/mTOR ↓; MAPK context-dependent)
4) Mitochondrial stress → apoptosis (cancer; often high concentration only)
5) Iron/copper chelation + lipid-peroxidation effects (ferroptosis overlap in select contexts)
Bioavailability / PK relevance: Many flavonoids have low oral bioavailability (rapid phase II conjugation: glucuronidation/sulfation; microbiome-derived metabolites). Plasma free aglycone levels are typically low; tissue effects often reflect metabolites and chronic exposure.
In-vitro vs oral exposure: Many “anti-cancer” cytotoxic effects occur at micromolar aglycone concentrations exceeding typical systemic exposure from diet/supplements (high concentration only), unless specialized formulations or local GI exposure is the intent.
Clinical evidence status: Broad epidemiology + small human trials for cardiometabolic/inflammatory endpoints; oncology evidence mostly preclinical/adjunct-hypothesis; no class-wide RCT oncology approval.
Flavonoids are classified into seven structural classes:
1.flavanones
-Nargenin, Naringin, Hesperetin, Isosakuranetin, Eriodictyol, Taxifolin
2.flavonols
-Quercetin, Myrcetin, Fisetin, Rutin Morin, Kaempferol
3.chalcones
-Butein, Xanthohumol, Isoliquintigenin, Cardamonin, Bavachalone, Xanthohumol, Phloretin
4.flavanols
-Catechin, Gallocatechin, Epicatechin, Epigallocatechin-3-galate
5.anthocyanidins
-Cyanidin
6.flavones
-Chrysin, Apigenin, Luteolin, Vitexin, Orientin, Bacalein, Wogonin, Oroxylin A, Saponarin
7.isoflavonoids
-Daidzein, Genistein, Glycitein
Flavonoids — Cancer vs Normal Cell Pathway Map (Class-Level)
| Rank |
Pathway / Axis |
Cancer Cells |
Normal Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
ROS |
↑ or ↓ (dose-dependent) |
↓ (physiologic / adaptive) |
P/R |
Redox reprogramming |
Class hallmark: hormesis. Low–moderate exposure often antioxidant/mitochondrial-protective; high exposure can be pro-oxidant/cytotoxic in cancer models. |
| 2 |
NRF2 (stress-defense; resistance role) |
↑ (context-dependent) |
↑ |
R/G |
Antioxidant gene induction |
Normal: cytoprotection. Cancer: NRF2 ↑ can reduce therapy sensitivity in some contexts (double-edged). |
| 3 |
NF-κB / inflammatory cytokine programs |
↓ |
↓ |
R/G |
Anti-inflammatory transcription suppression |
One of the most consistent class-level effects across models. |
| 4 |
PI3K/AKT/mTOR |
↓ (model-dependent) |
↔ / ↓ (metabolic/inflammatory improvement) |
R/G |
Reduced anabolic survival signaling |
Frequently reported but not uniform; often secondary to redox/inflammation changes. |
| 5 |
MAPK (ERK/JNK/p38) |
↑ stress MAPKs; ↓ ERK (context-dependent) |
↔ |
P/R |
Stress-response tuning |
JNK/p38 often ↑ with pro-apoptotic stress; ERK effects vary by compound/model. |
| 6 |
Intrinsic apoptosis (mitochondrial; caspases) |
↑ (high concentration only) |
↔ |
R/G |
Experimental tumor cytotoxicity |
Common in vitro endpoint; translation limited by PK and achievable free aglycone levels. |
| 7 |
Cell-cycle checkpoints |
↓ proliferation (model-dependent) |
↔ |
G |
Checkpoint enforcement |
Often downstream of kinase/redox modulation. |
| 8 |
Ferroptosis (iron/lipid peroxidation contexts) |
↑ or ↓ (compound-dependent) |
↔ |
R/G |
Lipid-ROS vulnerability shift |
Some flavonoids chelate iron (anti-ferroptotic) while others promote lipid peroxidation under stress (pro-ferroptotic); not class-uniform. |
| 9 |
HIF-1α / Warburg coupling |
↓ (model-dependent; high concentration only) |
↔ |
G |
Reduced hypoxia-adaptation signaling |
Reported in some models (often via PI3K/mTOR or ROS), but not a universal class mechanism at dietary exposure. |
| 10 |
Ca²⁺ / ER stress coupling |
↑ or ↔ (stress-dependent) |
↔ |
P/R |
UPR/excitability modulation |
Relevant mainly when apoptosis/UPR/excitotoxicity endpoints are measured; not a core class axis. |
| 11 |
Clinical Translation Constraint |
↓ (constraint) |
↓ (constraint) |
— |
PK + heterogeneity |
Major constraints: low bioavailability, metabolite-dominant exposure, large heterogeneity across subclasses, and frequent in-vitro concentration gaps. |
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
Flavonoids — AD relevance: Flavonoid-rich diets and select supplements are studied for neuroprotection via antioxidant/anti-inflammatory effects, cerebrovascular support, and synaptic plasticity signaling. Effects are generally supportive and exposure/metabolite dependent.
Primary mechanisms (conceptual rank):
1) ↓ Oxidative stress (ROS ↓; lipid peroxidation ↓)
2) ↓ Neuroinflammation (NF-κB/cytokines ↓; microglial tone ↓)
3) ↑ Synaptic plasticity signaling (BDNF/CREB ↑; network efficiency; chronic adaptation)
4) Vascular/endothelial support (NO signaling; perfusion coupling)
5) Secondary Aβ/tau pathway modulation (preclinical; not class-uniform)
Bioavailability / PK relevance: Brain effects likely mediated by metabolites and chronic intake; large variability by subclass and microbiome.
Clinical evidence status: Signals in small human trials (often with specific subclasses like cocoa flavanols/anthocyanins); AD disease-modification not established.
Flavonoids — AD / Neurodegeneration Pathway Map (Class-Level)
| Rank |
Pathway / Axis |
Cells |
TSF |
Primary Effect |
Notes / Interpretation |
| 1 |
ROS / lipid peroxidation |
↓ |
P/R |
Reduced oxidative burden |
Core neuroprotection rationale; effect depends on subclass/metabolites and baseline oxidative stress. |
| 2 |
Neuroinflammation (NF-κB, cytokines) |
↓ |
R/G |
Lower inflammatory stress |
Common class-level effect; relevant to microglial activation tone. |
| 3 |
NRF2 axis |
↑ (adaptive; context-dependent) |
R/G |
Stress-defense upshift |
Often supports antioxidant enzymes; magnitude varies widely by compound and exposure. |
| 4 |
BDNF / CREB / synaptic plasticity |
↑ (supportive) |
G |
Plasticity and learning support |
Frequently invoked across flavonoid cognition studies; typically requires weeks–months intake. |
| 5 |
Vascular/endothelial function (NO coupling) |
↑ (supportive) |
R/G |
Perfusion and neurovascular support |
Often attributed to flavanols/anthocyanins; supports “vascular cognitive impairment” framing. |
| 6 |
Aβ / tau-associated pathology |
↔ / ↓ (preclinical; compound-dependent) |
G |
Pathology modulation (hypothesis) |
Not class-uniform; strongest evidence is preclinical, with limited biomarker-confirmed human replication. |
| 7 |
Ca²⁺ homeostasis / excitotoxic vulnerability |
↔ / stabilized (indirect) |
P/R |
Excitotoxic buffering |
Secondary to antioxidant/mitochondrial support; include as primary only with explicit Ca²⁺ endpoints. |
| 8 |
Clinical Translation Constraint |
↓ (constraint) |
— |
Heterogeneity + metabolite dependence |
Large differences across subclasses, dosing, and microbiome; effects generally supportive, not disease-modifying. |
TSF legend: P: 0–30 min; R: 30 min–3 hr; G: >3 hr
|